Two experimental pills seem to pack a one-two punch for older diabetes drugs -- they not only help lower blood sugar levels but also help with weight loss.

The once-a-day medications are the first in a new class of type 2 diabetes drugs that manufacturers Merck & Co. and Novartis AG hope to win U.S. Food and Drug Administration approval for and to begin selling by year's end, the Associated Press reported Tuesday.

Merck's pill, Januvia or sitagliptin, lowered blood sugar levels by 0.67 percent for participants in a yearlong trial, or just as much as another, older drug, glipizide, the AP reported. Novartis' pill, Galvus or vildagliptin, reduced blood sugar levels by 1.9 percent when used with another older drug, pioglitazone, which reduces insulin resistance.

Excess weight is a common problem in type 2 patients. Both experimental pills helped patients maintain or even lose weight in the trials. Side effects of the pills included cold and flu-like symptoms and headaches.

Source: http://health.msn.com

####